Pharmaceutical major Eli Lilly has signed a worldwide collaboration agreement with medical device manufacturer Synthes to address the needs of patients with bone disorders.
The agreement will allow the joint development of early stage compounds to be used by patients in the care of orthopaedic surgeons, including those who suffer from osteoporosis, and the two companies will collaborate to develop osteoinductive medications.
Go deeper with GlobalData
Both companies will also conduct and fund work into evaluating Lilly’s osteoporosis drug Forteo for other orthopaedic uses, while Forteo will also be co-promoted in the US to orthopaedic surgeons under the agreement.
Lilly Bio-Medicines executive vice-president and president Bryce Carmine said, “We believe that patients worldwide will benefit from this collaboration because together we will be able to look for new ways to treat osteoporosis and bone fractures.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
